Search Results
Sep 07, 2026, 16:10 ET Lion Announces Plan to Implement ADS Ratio Change
offers a wide spectrum of products and services, including (i) total return service (TRS) trading, (ii) contract-for-difference (CFD) trading, and (iii) Over-the-counter (OTC) stock options trading. Additional information may be found at http://ir.liongrouphl.com.Forward-Looking
More news about: Lion Group Holding Ltd.
Sep 07, 2026, 15:45 ET Datavault AI, Inc. (DVLT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Plaintiff and other Class members, as alleged herein; (ii) artificially inflate and maintain the market price of Datavault AI securities; and (iii) cause Plaintiff and other members of the Class to purchase or otherwise acquire Datavault AI securities and options at artificially inflated prices.
More news about: Glancy Prongay Wolke & Rotter LLP
Sep 07, 2026, 10:05 ET Summary Notice to Stockholders of Supernova Partners Acquisition Company, Inc. as of August 27, 2021
should be finally appointed as Class representatives for the Class and Plaintiff's Counsel should be finally appointed as Class counsel for the Class; (iii) determine whether the proposed Settlement on the terms and conditions provided for in the Stipulation should be approved as fair, reasonable, and adequate
More news about: Levi & Korsinsky, LLP
Sep 07, 2026, 06:22 ET AtomVie Global Radiopharma feiert die große Eröffnung seiner neuen, hochmodernen Produktionsstätte für Radiopharmaka in Hamilton, Ontario
Dienstleistungen in Kombination mit einer spezialisierten Infrastruktur für die Entwicklung von Radiopharmazeutika von klinischen Studien der Phasen I bis III bis hin zur Markteinführung anbietet. AtomVie betreut derzeit internationale Kunden, die klinische Studien in über 28 Ländern weltweit durchführen. Weitere
More news about: AtomVie Global Radiopharma Inc.
Sep 07, 2026, 06:15 ET AtomVie Global Radiopharma célèbre l'inauguration officielle de sa nouvelle usine de fabrication de produits radiopharmaceutiques à la pointe de la technologie à Hamilton, en Ontario
associée à une infrastructure spécialisée dans le développement de produits radiopharmaceutiques, depuis les essais cliniques de phase I jusqu'à la phase III, puis à la commercialisation. AtomVie travaille actuellement avec des clients internationaux qui mènent des études cliniques dans plus de 28 pays à travers
More news about: AtomVie Global Radiopharma Inc.
Sep 07, 2026, 05:42 ET Nature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks
this progress is rentosertib (ISM001-055), the world's first drug candidate discovered and developed using generative AI, which has advanced to a Phase III trial evaluating for idiopathic pulmonary fibrosis (IPF). In addition, Insilico Medicine launched a comprehensive set of benchmarks that allow foundation
More news about: Insilico Medicine
Sep 06, 2026, 23:02 ET Bitmine Immersion Technologies（BMNR）宣佈 ETH 持有量達 590 萬枚，加密資產及現金持有總額達 156 億美元
億美元，包括 590 萬枚 ETH、總值 5.41 億美元的現金及有價證券，以及其他加密資產Bitmine 仍然得到頂級機構投資者（包括 ARK 的 Cathie Wood、MOZAYYX、Founders Fund、Bill Miller III、Pantera、Kraken、DCG、Galaxy Digital 和個人投資者 Thomas "Tom" Lee）支持，從而支援 Bitmine 收購 5% ETH 的目標康涅狄格州諾沃克
More news about: Bitmine Immersion Technologies, Inc.
Sep 06, 2026, 20:46 ET Peer-reviewed 411-patient study reports low infection rates with Myriad™ in complex soft tissue reconstruction
of complex soft tissue reconstruction procedures in a highly challenging real-world patient population. Approximately 59% of patients were ASA Class III or IV, indicating significant underlying systemic disease. In addition, 35% had diabetes, 30% had vascular disease and 23% used nicotine. The defects
More news about: Aroa Biosurgery
Sep 06, 2026, 20:01 ET Harbour BioMed Successfully Included in the Stock Connect, Reinforcing Capital Market Recognition
treatment of COPD and completed dosing of the first patients. Meanwhile, initial readouts from the Phase II/III POLARIS study in asthma are expected in the second half of 2026, with the first Phase III study of HBM9378 in asthma is expected to begin in the fourth quarter of 2026.Additionally, continued
More news about: Harbour BioMed
Sep 06, 2026, 14:39 ET Huawei präsentiert Flaggschiff-Produkte der nächsten Generation bei der globalen Innovationsveranstaltung „Chase the Wild" in München
Behandlungen herangezogen werden.[iii] Diese Funktion ist nicht für medizinische Zwecke bestimmt. Die Ergebnisse dienen lediglich als Anhaltspunkt und sollten nicht als Grundlage für medizinische
More news about: Huawei
Sep 06, 2026, 14:36 ET Huawei presenta sus productos insignia de última generación en el evento "Chase the Wild" en Múnich
diagnóstico o tratamiento médico.[iii] Esta función no está destinada a uso médico. Los resultados son solo de referencia y no deben utilizarse como base para un diagnóstico o tratamiento
More news about: Huawei
Sep 06, 2026, 14:34 ET Huawei dévoile ses produits phares de nouvelle génération lors de l'événement mondial de lancement de produits innovants « Chase the Wild » (« À la recherche de l'authenticité »), organisé à Munich
La fonctionnalité améliorée « Health Glance »[i] ainsi que les fonctionnalités « Health Insights »[ii] et « Healthy Living »[iii] rendent la gestion proactive de la santé plus intuitive que jamais.
More news about: Huawei
Sep 06, 2026, 02:26 ET Resonant Clinical Solutions renforce ses capacités de thérapies de pointe et de stockage cryogénique grâce à l'acquisition de Creapharm Bioservices
août 2025, a révélé que les molécules non de petite taille, y compris les modalités avancées, représentaient 46 % des essais cliniques de phase I à III lancés en 2024, contre 38 % cinq ans plus tôt.« Les entreprises du secteur des sciences de la vie ont de plus en plus besoin de partenaires disposant
More news about: Resonant Clinical Solutions
Sep 05, 2026, 14:24 ET DVLT Investors Have Opportunity to Lead Datavault AI Inc. Securities Fraud Lawsuit
overstated the volume of trading activity on the Datavault Platform, which was in fact minimal; (3) Datavault's undisclosed connections with Edward Withrow III, a convicted felon, when revealed, would cause Datavault AI to incur reputational harm; and (4) as a result, defendants' public statements
More news about: THE ROSEN LAW FIRM, P. A.
Sep 04, 2026, 22:00 ET Cogent Communications Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Cogent Communications Holdings, Inc. - CCOI
delivery even if timely provision was possible; (iii) as a result of (i)-(ii) above, the Company had materially misrepresented demand for its optical wavelength services and the nature of its "backlog" of wavelength orders; (iv) as a result of (i)-(iii) above, the Company was not on track to achieve its
More news about: ClaimsFiler
Sep 04, 2026, 22:00 ET Wix.com Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Wix.com Ltd. - WIX
to those offered by other companies; (ii) the Company had understated the costs associated with developing and promoting its AI product offerings; (iii) accordingly, Defendants overstated the commercial and financial benefits of Wix's AI product offerings; and (iv) as a result, Defendants' public statements
More news about: ClaimsFiler
Sep 04, 2026, 22:00 ET Primoris Services Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Primoris Services Corporation - PRIM
overruns, and project delays across six projects; (ii) as a result, the Company's full-year 2026 Adjusted EPS and Adjusted EBITDA guidance was overstated; (iii) the Company's projected 2026 Renewables revenue was overstated; and (iv) as a result, Defendants' positive statements about the Company's business,
More news about: ClaimsFiler
Sep 04, 2026, 22:00 ET EquipmentShare.com Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against EquipmentShare.com Inc. - EQPT
transactions; (ii) the Company had not terminated or substantially reduced a number of the transactions with entities owned or controlled by the co-founders; (iii) as a result, the Company's financial statements were materially misleading; and (iv) as a result of the foregoing, Defendants' positive statements about
More news about: ClaimsFiler
Sep 04, 2026, 22:00 ET York Space Systems Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against York Space Systems, Inc. - YSS
deceived the SDA with false advertising to win its contracts, cut corners, and delivered satellites whose mission-critical-software was not completed; and (iii) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading
More news about: ClaimsFiler
Sep 04, 2026, 22:00 ET PROCEPT BioRobotics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against PROCEPT BioRobotics Corporation - PRCT
consistently grown over time; (ii) as a result, the Company had accumulated cumulative excess field inventory of more than 10,000 handpiece units; (iii) this inventory imbalance would result in a significant sequential decline in U.S. handpiece unit sales and cause the Company to widely miss its annual
More news about: ClaimsFiler
Sep 04, 2026, 19:14 ET AtomVie celebra la inauguración de sus nuevas instalaciones de fabricación de última generación en Hamilton
logísticos y de calidad, combinados con una infraestructura especializada para el desarrollo de radiofármacos, desde los estudios clínicos de fase I a III hasta la comercialización. Actualmente, AtomVie presta servicios a clientes internacionales que llevan a cabo estudios clínicos en más de 28 países de
More news about: AtomVie Global Radiopharma Inc.
Sep 04, 2026, 18:40 ET EQPT Deadline: EQPT Investors with Losses in Excess of $100K Have Opportunity to Lead EquipmentShare.com Inc Securities Lawsuit
(ii) EquipmentShare had not terminated or substantially reduced a number of the transactions with entities owned or controlled by the co-founders; (iii) as a result, EquipmentShare's financial statements were materially misleading; and (iv) as a result of the foregoing, defendants' positive statements
More news about: THE ROSEN LAW FIRM, P. A.
Sep 04, 2026, 16:15 ET Fractyl Health, Inc. (GUTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Revita's clinical, regulatory, and commercial prospects were overstated, as was the REMAIN-1 Midpoint Cohort's ability to assess Revita's efficacy; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.What's The Next Step? Glancy
More news about: Glancy Prongay Wolke & Rotter LLP
Sep 04, 2026, 16:10 ET Kidney Patients Engage Congress During Summer Recess
participants in healthcare nor in the decisions that affect their ability to work and provide for their families," said AAKP President Edward V. Hickey, III, a chronic kidney disease patient. "They are informed, engaged citizens and a powerful voting constituency. Through the All Kidney Policy
More news about: American Association of Kidney Patients
Sep 04, 2026, 14:48 ET Resonant Clinical Solutions adquiere Creapharm Bioservices
reveló que los fármacos que no son de molécula pequeña, incluyendo las modalidades avanzadas, representaron el 46 % de los ensayos clínicos de fase I a III iniciados en 2024, frente al 38 % de cinco años antes."Las empresas de ciencias biológicas necesitan cada vez más socios con la experiencia especializada,
More news about: Resonant Clinical Solutions